

SINGAPORE
BIOTECH INVEST
21-22 March 2017
Singapore Exchange (SGX)

HONG KONG
BIOTECH INVEST
23-24 March 2017
KPMG Hong Kong

AUSTRALIA-CHINA
BIOTECH INVEST
27-28 March 2017
Shanghai Marriott Hotel City Centre

XIAOMING ZOU, PH.D., CHIEF EXECUTIVE OFFICER, EOC PHARMA

Dr. Zou currently acts as Chief Executive Officer, EOC Pharma, a venture backed, oncology focused Chinese biotech. He is responsible for the Company's overall strategy and operation. From March 2012 to December 2015, he was the Chief Business Officer of Eddingpharm, a China based specialty pharma. He led multiple cross board transactions for Eddingpharm, including commercial JV with Chiesi and Vascepa licensing from Amarin. From June 2010 to March 2012, he served as Executive Director, External Research and Development, Amgen Inc. and led partnering activities in inflammation and neuroscience therapeutic areas from R&D side. From May 2009 to June 2010, he served as Director, External Drug Discovery in Immuno-Inflammation CEDD of GSK. Prior to May 2009, he was Director, Senior Manager in Amgen's Licensing/External R&D Affair Department and worked on in-licensing and out-licensing projects in inflammation, cardiovascular, and neuroscience therapeutic areas. From June 2001 to May 2005, he served as Senior Scientist, Scientist in Amgen's Inflammation Research Department and led several early stage discovery projects. Xiaoming has a B.S. in biology and a M.S. in biochemistry from Tsinghua University and a Ph.D. in biochemistry and molecular biophysics from Columbia University.

